MAP2K2 and COVID-19: Regarding potential therapeutics for COVID-19, several candidates have been identified, including Gilteritinib (a specific MMP9 inhibitor), Pictilisib (targeting PI3K), Sorafenib (inhibiting RAF and growth factor receptors), RO5126766 (involved in inhibiting RAF and both MEK or MAP2K2), and Omipalisib (an inhibitor of mTOR and PI3K).